COMPANY
Neurotech Pharmaceuticals
FDA-approved therapeutic company FDA-cleared device company Clinical Phase 3
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Maintenance Technician | Cumberland, RI, US | Oct 9, 2026 | Oct 11, 2026 |
| Field Reimbursement Director | US | Sep 17, 2026 | Oct 11, 2026 |
Timeline
- Trial start 4: Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants source ↗
- Trial start Phase 3: A Study to Determine the Safety and Efficacy of NT-501 With MHFM source ↗
- FDA FDA New drug/biologic (novel): encelto (revakinagene taroretcel-lwey) — BLA125798, Mar 5, 2025. Applicant at approval: Neurotech Pharmaceuticals, Inc. source ↗
- Trial start Phase 2: Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2 source ↗
- Trial start Phase 3: A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol B source ↗
- Trial start Phase 3: A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A source ↗
- Trial start Phase 2: Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel) source ↗
- Trial start Phase 1/Phase 2: Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macula source ↗
- Trial start 2: A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel source ↗
- Trial start Phase 2: Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa source ↗
- Trial start Phase 1: Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel) source ↗
- Trial start Phase 2: A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa source ↗
- Trial start Phase 2: A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa source ↗
- Trial start Phase 2: A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration source ↗
Upcoming milestones
- Jan 15, 2032 (ESTIMATED) · 4 · Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants · NCT06971939
Clinical trials (lead sponsor) 13
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT06971939 | Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants | 4 | Recruiting | Nov 21, 2025 | Jan 15, 2032 (estimated) |
| NCT06397131 | A Study to Determine the Safety and Efficacy of NT-501 With MHFM | Phase 3 | Active, not recruiting | Mar 6, 2025 | May 1, 2026 (estimated) |
| NCT03071965 | Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel) | Phase 2 | Completed | May 12, 2017 | May 11, 2021 (actual) |
| NCT00447980 | A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa | Phase 2 | Completed | Jan 22, 2007 | Apr 19, 2010 (actual) |
| NCT00447954 | A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration | Phase 2 | Completed | Jan 5, 2007 | May 11, 2009 (actual) |
| NCT04729972 | Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2 | Phase 2 | Completed | Jul 21, 2021 | Dec 8, 2022 (actual) |
| NCT03319849 | A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol B | Phase 3 | Completed | Jan 22, 2018 | Aug 31, 2022 (actual) |
| NCT03316300 | A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A | Phase 3 | Completed | Nov 24, 2017 | Aug 31, 2022 (actual) |
| NCT00447993 | A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa | Phase 2 | Completed | Jan 8, 2007 | May 26, 2009 (actual) |
| NCT01530659 | Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa | Phase 2 | Completed | 2012-01 | Jul 1, 2019 (actual) |
| NCT02228304 | Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) | Phase 1/Phase 2 | Terminated | 2014-09 | 2016-04 (actual) |
| NCT01949324 | A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel | 2 | Completed | 2014-04 | Apr 14, 2017 (actual) |
| NCT01327911 | Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel) | Phase 1 | Completed | 2011-05 | 2016-09 (actual) |
FDA records (last 2 years)
- FDA New drug/biologic (novel): encelto (revakinagene taroretcel-lwey) — BLA125798, Mar 5, 2025. Applicant at approval: Neurotech Pharmaceuticals, Inc. source ↗
Open jobs 2
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Maintenance Technician | Cumberland, RI, US | Oct 9, 2026 | Oct 11, 2026 | Mid |
| Field Reimbursement Director | US | Sep 17, 2026 | Oct 11, 2026 | Senior |
Connect
See your connections at Neurotech Pharmaceuticals on LinkedIn (search by name, results not checked)